Molecular Analysis and Treatment Options of Thymic Malignancies
Launched by SHANGHAI CHEST HOSPITAL · Dec 28, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding thymic malignancies, which are cancers that occur in the front part of the chest. While surgery and radiation can help many patients, some still face challenges with their disease, leading to the need for better treatment options. The study aims to look closely at the genetic changes in these tumors to help identify how patients might respond to new targeted therapies. By creating a registry of patients with these types of cancers, researchers hope to improve how we diagnose and treat thymic malignancies in the future.
To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of a thymic malignancy. Participants should be able to understand the study and agree to sign a consent form. Those who join can expect to contribute to important research that may lead to better treatments tailored to their specific cancer. This study is currently recruiting participants of all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically proven diagnosis of thymic malignancies
- • 18 years of age or older
- • Ability to understand and the willingness to sign a written informed consent document
About Shanghai Chest Hospital
Shanghai Chest Hospital is a leading medical institution in China, renowned for its specialized expertise in respiratory and thoracic diseases. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical research and improving patient outcomes through innovative therapies and treatments. With a strong emphasis on collaboration and scientific rigor, Shanghai Chest Hospital actively engages in a variety of clinical trials aimed at exploring novel interventions and enhancing the understanding of pulmonary health. The hospital's state-of-the-art facilities and commitment to patient-centered care position it as a key player in the global research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials